CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as powered resection instruments, fluid management and visualization systems, and related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solutions comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures; and products to treat diseases of dilation, hemostasis, biliary, stricture management, and infection prevention, as well as ECG electrodes, EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.…
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CONMED (NYSE: CNMD) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 3,900 employees.
The shares were at 46.56 USD on 20 November 2026, up 11.8% over 52 weeks. Its 52-week range is 31.44 USD to 54.56 USD: the price is 14.7% below the high and 48.1% above the low.
At a market capitalisation of 1.39B USD, it trades at 19.3 times trailing earnings and 9.8 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a discount of 24% for CNMD.
CONMED reports return on equity of 4.6%, an operating margin of 10.2% and revenue down 0.7% year over year.
Its debt exceeds its cash by 767.89M USD, a debt-to-equity ratio of 0.81. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Hold; their mean price target of 46.83 USD is 0.6% above the current price. The next earnings report is expected on 27 January 2027.